PATRYS Ltd (PAB) - Total Liabilities

Latest as of June 2025: AU$1.01 Million AUD ≈ $711.96K USD

Based on the latest financial reports, PATRYS Ltd (PAB) has total liabilities worth AU$1.01 Million AUD (≈ $711.96K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

PATRYS Ltd - Total Liabilities Trend (2007–2025)

This chart illustrates how PATRYS Ltd's total liabilities have evolved over time, based on quarterly financial data. See PATRYS Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

PATRYS Ltd Competitors by Total Liabilities

The table below lists competitors of PATRYS Ltd ranked by their total liabilities.

Company Country Total Liabilities
Sejin T.S Co.Ltd
KQ:067770
Korea ₩1.08 Billion
Sama Resources Inc.
V:SME
Canada CA$63.28K
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
USA $201.59 Million
Kim Hin Joo
KLSE:0210
Malaysia RM23.55 Million
Jatcorp Ltd
AU:JAT
Australia AU$18.64 Million
Rubicon Water Ltd
AU:RWL
Australia AU$44.07 Million
Metalsgrove Mining Ltd
AU:MGA
Australia AU$123.69K
REMAK SA
WAR:RMK
Poland zł94.32 Million

Liability Composition Analysis (2007–2025)

This chart breaks down PATRYS Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PATRYS Ltd market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.73 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.74 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.58 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PATRYS Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PATRYS Ltd (2007–2025)

The table below shows the annual total liabilities of PATRYS Ltd from 2007 to 2025.

Year Total Liabilities Change
2025-06-30 AU$1.01 Million
≈ $711.96K
+45.54%
2024-06-30 AU$691.37K
≈ $489.18K
+0.65%
2023-06-30 AU$686.90K
≈ $486.02K
+26.54%
2022-06-30 AU$542.83K
≈ $384.08K
-36.13%
2021-06-30 AU$849.86K
≈ $601.33K
+70.52%
2020-06-30 AU$498.38K
≈ $352.64K
-21.81%
2019-06-30 AU$637.42K
≈ $451.02K
-6.50%
2018-06-30 AU$681.77K
≈ $482.40K
+37.58%
2017-06-30 AU$495.53K
≈ $350.62K
-20.11%
2016-06-30 AU$620.26K
≈ $438.87K
-22.69%
2015-06-30 AU$802.28K
≈ $567.67K
-66.28%
2014-06-30 AU$2.38 Million
≈ $1.68 Million
+120.06%
2013-06-30 AU$1.08 Million
≈ $765.05K
+17.99%
2012-06-30 AU$916.36K
≈ $648.38K
-33.63%
2011-06-30 AU$1.38 Million
≈ $976.96K
+28.55%
2010-06-30 AU$1.07 Million
≈ $760.00K
-26.41%
2009-06-30 AU$1.46 Million
≈ $1.03 Million
+65.44%
2008-06-30 AU$882.30K
≈ $624.28K
-62.55%
2007-06-30 AU$2.36 Million
≈ $1.67 Million
--

About PATRYS Ltd

AU:PAB Australia
Market Cap
$10.85 Million
AU$15.33 Million AUD
Market Cap Rank
#27153 Global
#1334 in Australia
Share Price
AU$0.05
Change (1 day)
-2.17%
52-Week Range
AU$0.00 - AU$0.05
All Time High
AU$0.07
About

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more